Recently, TQB6457 for injection, a Class 1 innovative drug submitted by CTTQ Pharma, a core member company of Sino Biopharm (1177.HK), has officially received implied permission for clinical trials from the Center for Drug Evaluation (CDE), NMPA, for the treatment of advanced malignant neoplasms. As the world's first fixed-dose combination of a CCR8 monoclonal antibody and a PD-1 antibody to enter the clinical research stage, this product aims to improve medication adherence and break medication restrictions for patients with advanced tumors by exploring the use of a single formulation to replace combination therapy. 

CCR8 is a potential target specifically and highly expressed on the surface of regulatory T cells (Tregs) in the tumor microenvironment, playing a key role in recruiting Tregs to the tumor site. PD-1 is a classic immune checkpoint protein, and tumor cells can trigger immunosuppressive mechanisms by binding PD-1 with PD-L1. As a combination formulation of the two, TQB6457 can simultaneously and precisely target the two key immuno-oncology targets, CCR8 and PD-1. On one hand, it depletes FOXp3(+)CCR8(+) Treg cells infiltrating the tumor, relieving Treg-mediated immunosuppression. On the other hand, it blocks the PD-1/PD-L1 pathway, activating the body's anti-tumor immune response, achieving a synergistic anti-tumor effect of "1+1>2". 

Previous clinical study results have shown that the combination of a CCR8 antibody and a PD-1 antibody has a favorable safety profile, with manageable and tolerable toxicity when combined with chemotherapy. A preliminary synergistic effect has been observed, with an expected efficacy superior to PD-1 antibody monotherapy. While retaining the potential efficacy advantages of combination therapy, TQB6457 significantly shortens patient infusion time and simplifies the medication process in clinical practice. For sequential administration, the total fluid volume of the combination formulation is lower than that of the traditional combination model, which can reduce the treatment safety risks for patients with conditions like heart failure that require restricted fluid intake. 

Disclaimer:

1. This press release is intended to facilitate the communication and exchange of medical information and is for reference by healthcare professionals only. It is not for advertising purposes.

2. The company does not recommend any drugs and/or indications.

3. The information contained in this press release is for reference only and cannot replace professional medical guidance in any way, nor should it be considered as a diagnosis or treatment recommendation. If you wish to understand specific disease diagnosis and treatment information, please follow the advice or guidance of a physician or other healthcare professional. 

Forward-looking Statements:

This press release contains certain forward-looking statements, including statements regarding the clinical development plan, expected clinical benefits and advantages, commercialization outlook, the likelihood of clinical benefit for patients, and potential commercial opportunities for [TQB6457]. Words such as "expect", "believe", "continue", "may", "estimate", "hope", "intend", "plan", "potential", "predict", "project", "should", "will", "propose", and similar expressions are intended to identify forward-looking statements, but not all forward-looking statements contain these identifying words. These forward-looking statements are predictions or expectations made by the company based on currently available data and information, and actual results may differ materially from these forward-looking statements due to uncertainties or risks such as policy, R&D, market, and regulatory factors. Current or potential investors are advised to carefully consider the potential risks and should not place undue reliance on the forward-looking statements in this press release, which contain information only as of the date of this press release. Unless required by law, the company undertakes no obligation to update or revise any forward-looking statements in this press release as a result of new information, future events, or other circumstances.